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Abstract: Dietary flavones have promising chemoprotective properties, in particular with 
regard to cancer, but problems with low oral bioavailability and sometimes unacceptable 
toxicity have made their use as protective additives to normal diets questionable. However, 
methylation of free phenolic hydroxyl groups leads to derivatives not susceptible to 
glucuronic acid or sulfate conjugation, resulting in increased metabolic stability. 
Methylation also leads to greatly improved transport through biological membranes, such 
as in intestinal absorption, and much increased oral bioavailability. Recent studies also 
indicate that methylation results in derivatives with increasing potency to kill cancer cells. 
They also show high potency towards inhibition of hormone-regulating enzymes, e.g., 
aromatase, important in the causation of breast cancer. Methylation of the flavones may 
also result in derivatives with diminished toxic side-effects and improved aqueous 
solubility. In conclusion, it appears that methylation of dietary flavones as well as of other 
food products may produce derivatives with much improved health effects. 
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1. Introduction 
Dietary flavonoids and other polyphenols have long been considered potential chemoprotective 
agents, mainly in cardiovascular disease and cancer but also in many other disease conditions [1]. This 
has been supported by numerous cellular studies. This has resulted in an explosion of the market for 
supplements based on more or, frequently, less scientific evidence. However, in more recent years, in 
particular in the area of cancer, increasingly in depth research has established these compounds as truly 
remarkably diverse regarding their multiple cellular mechanisms of chemoprotective action. Whereas 
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initially the flavonoids were purely regarded as antioxidants, it is now clear that this is not the major 
mechanism of their actions [2]. Instead, a wide range of signaling targets involved in both cancer 
initiation and promotion have been identified. 
The flavonoids have been shown to  prevent important carcinogens such as the polyaromatic 
hydrocarbons from covalently binding to DNA to initiate the carcinogenic process. These effects are 
mediated by inhibition of the bioactivating enzymes, such as CYP1A1 and CYP1B1 [3–6], and the 
transcription of these CYP isoforms [6–8]. The chemoprotective function of the flavonoids also 
includes induction of bioinactivating enzymes such as UDP-glucuronosyltransferase [9], NAD(P)H: 
quinone oxidoreductase [10] and glutathione S-transferase [11]. 
Extensive studies have focused on effects of dietary flavonoids on cancer cell proliferation and 
apoptosis. This includes effects on VEGF and HIF-1 expression via PI3K/AKT pathways [12] or via 
ARNT [13]. Various flavonoids have also been shown to inactivate EGFR [14] and to inhibit 
thioredoxin reductase [15] and thymidylate synthase [16] as well as to affect cancer cell resistance by 
targeting the molecular chaperone glucose-regulated protein 78 [17]. Those are all examples of 
important targets for cancer chemoprevention. 
However, when attempting to extrapolate from those cellular studies to the in vivo situation, the 
results are mainly disappointing. Thus, animal studies as well as attempted similar studies in humans 
have not lived up to the expectations from the in vitro studies. The main problem is the very poor oral 
bioavailability of these flavonoids, mainly due to extensive intestinal and hepatic metabolism.  
2. Metabolic Stability and Membrane Transport 
Most naturally-occurring flavonoids exist as glycosides with various sugars. Numerous studies 
conclude that these glycosides are not absorbed per se but require prior hydrolysis to the aglycones in 
the intestinal lumen [18–22], which appears to be an efficient process. Our concerns in this review will 
therefore be focused on the aglycones. 
The bioavailability of flavonoids is the cornerstone for extending their in vitro biological functions 
to humans in vivo [21,23,24]. Although many flavonoids are absorbed and reach the systemic 
circulation to some extent, the concentrations in most cases will not be high enough to exert their 
cellular biological functions in vivo. This has been shown in clinical studies of some of the more 
common dietary flavonoids and other polyphenols, such as chrysin [25], resveratrol [26,27], quercetin 
[23,28] and the tea flavonoids [29,30]. Taking all the observations in the flavonoid literature together, 
it appears that extensive conjugation of the free hydroxyl groups is the main reason for the low oral 
bioavailability of the dietary flavonoids [21,23,24], although transporters may play a role [31–33]. 
However, whether oxidation also might be important, at least for some flavonoids [3,34,35], is much 
less clear. Otake et al. clearly demonstrated a role for CYP-mediated metabolism of several flavonoids 
[36,37], first assessing human liver microsomal oxidation, including the CYP isoforms involved, in 
that commonly used in vitro model. Other microsomal studies of CYP-mediated oxidation include the 
flavonoids biochanin A, prunetin, formononetin, genistein and tangeretin [38,39]. However, isolated 
microsomes do not reflect the complete metabolic profile, in particular for those flavonoids mainly 
metabolized by conjugation. Thus, using the human liver homogenate 9,000 g supernatant (S9 
fraction) as well as freshly plated human hepatocytes with the flavonoid galangin (3,5,7-trihydroxy-
flavone) as the substrate, the role of the CYPs decreased dramatically in comparison with Int. J. Mol. Sci. 2009, 10                 
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glucuronidation and sulfation. In the S9 fraction, oxidation accounted for only about 2% of total 
metabolism of galangin [37]. This was very well reflected in the metabolism by the human 
hepatocytes, the model system that is closest to the in vivo situation [37]. 
Methylation was examined in our laboratory as a generic approach to cap all free hydroxyl groups 
in the flavonoids. We focused our interest exclusively on flavones, a flavonoid subclass, see structures 
in Figure 1.  
Figure 1. (a) Basic flavone skeleton; (b) structures of some common dietary and other 
model flavones. 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
Polymethoxyflavones such as tangeretin, sinensetin and nobiletin, containing 5-7 methoxy groups, 
are found in high concentrations in the peel of various Citrus species, whereas the many hydroxylated 
flavones [40,41] predominate in the juice. The smaller methoxyflavones, with one to three methoxy 
groups and without any hydroxyl groups, are present in plants that are less utilized for human 
consumption compared to the polymethoxyflavones. For example, 5,7,4’-TMF, although present in a 
Citrus species [42], also is present in other plants used in folk medicine [43,44]. 7,4’-DMF has been 
found in neotropical nutmeg species [45,46]. 5,7-DMF is highly abundant in pepper tree leaves [47]. 
While none of the small methoxylated flavones are abundant in the common human diet, the mounting 
evidence of protective properties of these flavones may lead to increased use of their natural sources. 
Many of these compounds are also available in synthetic form. Parts of this topic have been addressed 
in previous publications [48–50]. 
Our hypothesis  was that blocking the free hydroxyl groups of the flavones should eliminate 
conjugation as the primary metabolic pathway. If the oxidative demethylation rate was slow enough, 
big improvements in metabolic stability may result. Figure 2 shows the metabolic depletion of 
unmethylated as well as methylated polyphenols in pooled human liver S9 fractions supplemented with 
the cofactors for glucuronidation, sulfation and oxidation. Figure 2a shows the metabolic stability for 
the unmethylated common dietary flavone quercetin, demonstrating rapid disappearance of the parent 
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compound due to extensive metabolism. For quercetin this was due mostly to glucuronidation [51]. 
This is consistent with its very low oral bioavailability in humans [28]. Similar results were obtained 
for three unmethylated flavones, 7-hydroxyflavone (7-HF), chrysin (5,7-dihydroxyflavone) and 
apigenin (5,7,4’-trihydroxyflavone) (open symbols, Figures 2B-D). 
Figure 2. Time-dependent metabolic depletion of unmethylated and methylated flavones in 
pooled human liver S9 fraction (modified from ref. [51]). (a) quercetin; (b) 7-MF (filled 
symbols) and 7-HF (open symbols); (c) 5,7-DMF (filled symbols) and chrysin (open 
symbols); (d) 5,7,4’-TMF (filled symbols) and apigenin (open symbols).   
Human liver S9 fraction was incubated with UDPGA, PAPS and NADPH and 5 µM 
flavone and analyzed by HPLC. 
 
 
 
 
 
 
 
 
 
 
 
 
* Significantly higher than the corresponding unmethylated flavone after the same incubation time. 
 
For the unmethylated flavones the disappearance from the S9 incubation medium was very rapid, 
not significantly different from quercetin. For 7-HF sulfation dominated slightly, whereas for chrysin 
and apigenin glucuronidation was by far the major metabolic pathway. In sharp contrast, the 
corresponding methylated flavones, 7-methoxyflavone (7-MF), 5,7-dimethoxyflavone (5,7-DMF) and 
5,7,4’-trimethoxyflavone (5,7,4’-TMF) (closed symbols), all showed remarkable stability [51]. 
When examining the absorption of the same three unmethylated versus methylated flavones in 
Caco-2 cell monolayers, considered the best model of human intestinal absorption [52,53], 
considerably higher permeability was observed for the methylated compounds (Figure 3). The reason 
for this higher transport rate cannot be deduced from these experiments, although it most likely is 
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related to the greater metabolic stability of the methylated compounds. The unmethylated flavones 
were mainly metabolized by sulfation, consistent with the fact that sulfation in the intestine is 
relatively more important than glucuronidation. Only for chrysin was there a significant contribution 
from glucuronidation [51]. 
Figure 3. Caco-2 cell transport of methylated versus unmethylated flavones (modified 
from ref. [51]). (a) 7-MF (filled squares) and 7-HF (open squares); (b) 5,7-DMF (filled 
diamonds) and chrysin (open diamonds); (c) 5,7,4’-TMF (filled circles) and apigenin (open 
circles). A 5 µM concentration of the flavones (10 µM for 5,7-DMF and chrysin) in 
transport buffer was added to the apical chambers of Transwells. Samples were taken from 
the basolateral side at 0.5, 1, 3 and 6 hr.  
 
 
 
 
 
 
 
* Significantly higher than the corresponding unmethylated flavone after the same incubation time. 
 
Based on these observations with the hepatic S9 fraction and the Caco-2 cells, it could be predicted 
that the oral bioavailability of 5,7-DMF would be much greater than that for chrysin. This was tested 
directly in vivo in the rat [54]. 5,7-DMF and chrysin were co-administered by oral gavage at 5 mg/kg, 
which is a common dose when chrysin is used as a dietary supplement in humans. Only 5,7-DMF was 
detectable in the plasma, peaking at 2.3 µM at 1 hr (Figure 4a). 5,7-DMF was also easily detectable in 
liver, lung and kidney tissue at quite high concentrations compared to plasma (Figure 4b). Chrysin was 
not detectable in any tissue but started to appear in the fecal pellets in the intestinal lumen after 2 hr 
(not shown). 
Thus, it appears that the methylated flavones gain their high metabolic stability as well as high 
membrane transport properties due to the fact that they are missing a free hydroxyl group, which 
otherwise can serve as an acceptor for conjugating glucuronic and sulfate groups. The methylated 
flavones could be O-demethylated by cytochrome P450 enzymes and then conjugated as discussed 
above, although the two conjugation reactions are much preferred to oxidation. To better understand 
these relationships, we determined the oxidative O-demethylation of 15 methoxyflavones using human 
liver microsomes as the cytochrome P450 source. The oxidation rates, calculated as Clint, varied 
dramatically, as much as 20-fold (Table 1) [55]. The finding that all four methoxyflavones showing the 
highest resistance to microsomal oxidation contained a methoxy group in the 5-position indicates that 
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the 5-methoxy group confers special resistance to oxidative metabolism. The number of methoxy 
groups does not appear to have any effect on the susceptibility to oxidation, as 5-MF, 5,7-DMF and 
sinensetin with one, two and five methoxy groups, respectively, were quite stable, whereas 7-MF, 7,3’-
DMF and tangeretin with the same numbers of methoxy groups were much less stable. The two 
flavones with a single methoxy substituent in the B-ring, i.e., 3’-MF and 4’-MF, were the 
methoxyflavones most prone to oxidation. The two tested flavones with both hydroxy and methoxy 
groups, i.e., kaempferide and especially tectochrysin, were more susceptible to oxidation than most of 
the fully methylated flavones. 
Figure 4. Plasma and tissue levels of 5,7-DMF and chrysin after oral administration of  
5 mg/kg in rats. (a) Plasma 5,7-DMF (no chrysin could be detected); (b) tissue 5,7-DMF in 
liver (), lung () and kidney (Δ); (mean ± SEM of 5 animals at each time-point) 
(modified from ref. [54]). 
 
 
 
 
 
 
 
 
 
 
Table 1. Elimination half-life and intrinsic clearance of methoxyflavones (5 µM) incubated 
with human liver microsomes in the presence of NADPH [55]. 
Flavone  Half-life (min)  Clint (ml min
-1 kg
-1) 
5,7-DMF 97.1  12.8 
5-MF 68.2  18.3 
Sinensetin 44.8  27.8 
5,7,4’-TMF 33.3  37.4 
3’,4’-DMF 30.9  40.3 
7,4’-DMF 28.6  43.6 
5,3’-DMF 20.8  60.0 
Tangeretin 17.4  71.7 
7-MF 15.7  79.4 
Kaempferide 15.2  82.0 
7,3’-DMF 13.6  91.7 
5,4’-DMF 10.5  119.0 
3’-MF 8.9  140.0 
4’-MF 7.8  161.0 
Tectochrysin 4.4  283.0 
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3. Anticancer and Hormonal Effects 
It is quite clear from the above that methylation of free hydroxyl groups in the flavones results in 
metabolically more stable derivatives with superior membrane-penetrating properties and thus vastly 
improved bioavailability. This may also be expected to lead to greater biological effects. This was 
tested in several cancer vs. non-cancer cells. 
Central to protective effects by dietary flavonoids at the promotion stage of chemically-induced 
carcinogenesis is the ability to inhibit cell proliferation. The damage that the carcinogens have inflicted 
on cellular DNA during the initiation stage is being propagated into a new cell population. This 
machinery, i.e., clonal expansion, is highly complex, geared towards giving the cells immortality by 
stimulating mitogenesis and/or decreasing cell death by inhibiting apoptosis. Protective effects at this 
stage are critically important. This has been demonstrated in cell culture with unmethylated flavonoids 
and other polyphenols, as discussed briefly in the Introduction, affecting numerous signal transduction 
pathways. 
Some of the polymethoxylated citrus flavonoids have also in preliminary studies demonstrated 
antiproliferative properties [56,57]. However, the effect of methylation of the flavonoids on their 
antiproliferative effects has not been clarified. This is in particular true for the smaller methoxylated 
flavones. Many studies in the past have assumed that the free hydroxyl groups of the flavonoids and 
other polyphenols are necessary for biological effects. The long held belief that their antioxidant 
properties were responsible for the antiproliferative effects has now been found not to be true [2]. 
The antiproliferative effects of methoxylated versus hydroxylated flavones were directly compared 
in SCC-9 human oral squamous carcinoma cells. The effects of treatment with 5,7,4’-trimethoxy-
flavone (5,7,4’-TMF) versus 5,7,4’-trihydroxyflavone (apigenin), one of the most thoroughly studied 
unmethylated flavones, are shown in Figure 5a. 5,7,4’-TMF was about eight times more potent than 
apigenin, with an IC50 value of 5 µM. The IC50 value of 40 µM for apigenin agrees with most previous 
studies of this flavone in various human cancer cell lines [58–60]. Very similar results as with 5,7,4’-
TMF were obtained for 5,7-dimethoxyflavone (5,7-DMF) compared to its unmethylated analog 5,7-
dihydroxyflavone (chrysin) (Figure 5b) [54]. The greater potency of the two methoxylated versus the 
two hydroxylated flavones could conceivably be due to greater cell uptake of the methoxylated 
flavones. However, after incubation of SCC-9 cells for up to 24 hr with 25 µM 5,7-DMF or chrysin, 
the uptake was rapid and virtually identical for the two compounds [54]. 
A small number of additional methoxylated flavones have been investigated for antiproliferative 
effects in the SCC-9 cells [54]. The calculated IC50 values were 36.5 µM (7-MF), 24.2 µM (7,4’-
DMF), and 19.3 µM (tangeretin), respectively. In addition, 5,4’-DMF, 5,3’-DMF and 7,8-DMF 
showed weaker effects. In MCF-7 human breast cancer cells, the 5-, 7-, and 5,7-methoxyflavanones, 
i.e., without the C-ring double bond, showed growth inhibitory effects with IC50 values around 35 µM, 
as measured by the MTT assay [61]. In these cells, 5-methoxyflavone was almost as potent as the 
flavanones and 7-methoxyflavone was more potent than its hydroxyl analog. 
In a model of human gastrointestinal malignancies, a very recent study found the anticancer 
efficacy of a methylated apigenin analog superior to that of apigenin and tricin, an only partially 
methylated flavone [62]. This finding is very similar to the study in the oral cancer cells above, 
possibly for the same reasons.  Int. J. Mol. Sci. 2009, 10                 
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Figure 5. Effect of methylated flavones (a) 5,7,4’-TMF and (b) 5,7-DMF compared to 
unmethylated analogs apigenin and chrysin, respectively, on SCC-9 cell proliferation 
(modified from ref. [54]). Cell proliferation, expressed as percent of control (DMSO-
treatment), was measured as BrdU incorporation into cellular DNA after a 24-h exposure 
of the cells to the flavones. Mean values ± SEM (n = 10). The numbers shown in the figure 
are the calculated IC50 values. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Significantly lower than control, P < 0.05. # significantly higher than control, P < 0.05. 
 
To determine whether the growth inhibitory effect was accompanied by cell cycle arrest, SCC-9 
cells were treated with two pairs of flavones for 72 h. These experiments showed that apigenin caused 
a distinct increase in the G2/M phase population, as has previously been shown [59,60]. In contrast, 
5,7,4’-TMF caused a dose-dependent increase in the G1 phase, significant already at 5 µM, with a 
concomitant decrease in the S phase [54]. Identical results were obtained for 5,7-DMF compared to its 
unmethylated analog chrysin (Figure 6). The results seen by flow cytometry were thus very similar to 
those seen in the cell proliferation assay.  
To determine if the potent antiproliferative effects observed by the methoxylated flavones on the 
SCC-9 cells were selective for cancer vs. noncancer cells, the effects of 5,7-DMF and chrysin in two 
additional cancer cell lines were compared with those in two noncancer cell lines. In the FaDu human 
larynx SCC cells, 5,7-DMF and chrysin showed similar potency as 5,7-DMF in the SCC-9 cells (IC50 
8–10 µM). In the MCF-7 human breast cancer cells, both compounds again had similar but slightly 
lower potency with IC50 values of 10-20 µM. In contrast, two normal but transformed human cell lines, 
i.e., the HET-1A esophageal cells [63] and the BEAS-2B bronchial epithelial cells [64], were much 
less sensitive to both 5,7-DMF and chrysin with IC50 values > 100 µM.  
The mechanism of the potent antiproliferative effects of 5,7,4’-TMF and 5,7-DMF compared to 
their unmethylated analogs has not yet been addressed. However, recent thinking [65,66] suggests that 
the effect of these methoxyflavones on the AhR-mediated expression, in particular of CYP1A1, may 
have a direct effect on cell cycle regulation. This is too early to conclude, but may provide a novel set 
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of mechanisms to pursue, connecting cancer initiation with promotion, including the protective effects 
of the methoxyflavones.  
Figure 6. Effect of 5,7-DMF (a) compared to chrysin (b) and 5,7,4’-TMF (c) compared to 
apigenin (d) on SCC-9 cell cycle progression (modified from ref. [54]). Cells were exposed 
to varying concentrations of flavones for 48 h. The percentage of cells in G1, S and G2/M 
phase was measured by flow cytometry after propidium iodide staining. Mean values of 3 
experiments with duplicate samples are shown. * Significantly different from control,   
P < 0.05 or better. 
 
It is however true that many flavonoids have profound effects on both CYP1A1 and CYP1B1 
expression, both at the protein and the mRNA levels. These effects appear to be greater for the 
methylated versus the unmethylated flavones. The effects are cell-specific, as seen for hepatocytes 
(CYP1A1) [6], lung cells (CYP1A1 and CYP1B1) [8], oral cells (CYP1B1 and CYP1A1) [5] and 
esophageal cells (CYP1B1) [67]. Int. J. Mol. Sci. 2009, 10                 
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A specific cancer protective mechanism against hormone-sensitive cancers, which has received 
much interest lately, is through downregulation of estrogen concentrations. Thus, two methoxylated 
flavones, 7-methoxyflavone and 7,4’-dimethoxyflavone, have been shown to be potent inhibitors of 
aromatase, the enzyme responsible for converting testosterone to estradiol (IC50 values of 2–9 µM) 
[68]. Some flavonoids, notably chrysin, have been shown to be potent aromatase inhibitors in vitro 
[69]. However, due to lack of bioavailability [25,51,70], their claims of therapeutic efficacy have never 
been substantiated. With the methoxylated flavones, this clinical application may be realistic. 
4. Toxic Side-Effects of Methylated Derivatives 
In spite of the evidence of protective effects of flavonoids in many disease states, it is important to 
realize that toxicity may occur, in particular if ingesting excessive amounts. The latter may sometimes 
occur after using flavonoids as food supplements. Although being antioxidants, flavonoids can also 
have prooxidants properties [71], capable of causing oxidative stress, for example through peroxidase-
induced phenoxyl radicals [72]. Thus, the flavonol quercetin has been shown to undergo cellular 
oxidation mediated either by peroxidases [73] or by nonenzymatic chemical reactions and covalent 
binding to cellular protein and DNA [74,75]. 
Figure 7. Trout cells after 24-hr exposure to medium, vehicle control, or 25 µM flavones. 
Dead or dying cells are indicated by arrows (modified from ref. [76]). 
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To investigate toxic and other effects of xenobiotics in general, cell culture models from a variety of 
hosts have been used, among which cultured fish cells have found utility in many areas [76]. Rainbow 
trout hepatocytes have found special utility [77]. This non-cancer cell model was used to examine for 
toxicity of a few flavones as well as methylated analogs [76]. Growth and health of the trout hepato-
cytes were monitored by microscopy after treatment with flavonoids or vehicle (DMSO) (Figure 7).  
Treatment with DMSO had no visible effect on growth patterns even up to 48 hr. At 24 hr, all 
flavonoids caused some inhibition of cell growth, as monitored by confluence levels and protein 
measurements. Two of the compounds with free hydroxyl groups, i.e., chrysin and apigenin, 
dramatically reduced cell numbers. Large gaps were seen in the previously semiconfluent monolayers. 
Additionally, cells were observed lifting off and floating in the medium. In sharp contrast, the 
methylated chrysin analog 5,7-DMF, showed no toxicity even at a concentration of 25 µM. Another 
methylated flavone, i.e., 3’,4’-DMF, an aryl hydrocarbon receptor antagonist [78], showed similar lack 
of toxicity. Chrysin produced a clear concentration-dependent toxicity (Figure 8). A concentration of  
2 µM showed no visual adverse effects, whereas 10 µM was clearly toxic and 25 µM even more so. 
Trout cell proliferation was measured as BrdU incorporation into newly synthesized DNA of 
actively proliferating cells. The methoxylated flavone 5,7-DMF showed minimal inhibition with an 
IC50 value of 50-100 µM. This is similar to the response to 5,7-DMF in two normal human cell lines, 
the lung BEAS-2B cells and the esophageal HET-1A cells [54]. In contrast, chrysin was exceedingly 
potent, producing an IC50 value as low as 2 µM [76].  
Figure 8. Confluent trout cells treated for 48 hr with various concentrations of   
chrysin [76]. 
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The mechanism of the observed cell toxicity is not clear from these studies. One possibility is the 
presence of peroxidases-like activity in these cells, similar to the human myeloid HL-60 cells [76]. 
Thus, chrysin was oxidized by human myeloperoxidase, but 5,7-DMF was not. 
5. Solubility of Methylated Derivatives 
It has long been recognized that the aqueous solubility of flavonoids in general is quite low. This 
has commonly been observed in in vitro experiments. However, in vivo, low oral bioavailability has 
also been attributed to inadequate solubility of the flavonoids in the gastrointestinal tract, in addition to 
presystemic metabolism. This is certainly true for the extensively studied flavonoid quercetin in animal 
studies where very large oral doses were used [79], but also in human studies [80]. Low solubility is an 
obvious problem in general when attempting to design oral dosage regimens. The effect of methylation 
on the aqueous solubility was therefore examined for 5,7-DMF compared to its unmethylated analog 
chrysin. The expectation was that the solubility of chrysin would be higher due to its two free hydroxyl 
groups. The experiments were performed by measuring the UV absorption of the flavonoids after 
removing undissolved material by centrifugation. Figure 9 shows that 5,7-DMF is soluble in water or 
pH 7.4 Hanks’ buffer solution up to at least 100 µM. In contrast, chrysin reached maximum solubility 
at around 20 µM [81]. This surprising finding should be extended to other methylated and 
corresponding unmethylated flavones. If confirmed, this should favor the use of methylated flavones. 
Figure 9. Solubility of 5,7-DMF and chrysin in aqueous solution, i.e., deionized water 
(open symbols) and Hanks’ buffered salt solution (closed symbols). Measurements were 
made by UV at 265 nm after removal of insoluble material. Each point is the mean of two 
determinations [81]. 
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6. Conclusions and Future Studies 
Methylated flavones comprise a subclass of flavones with distinct properties. In first hand, 
methylation of the free hydroxyl groups in the flavones dramatically increases their metabolic stability 
by preventing the formation of glucuronic acid and sulfate conjugates. This also results in increased 
membrane transport, leading to facilitated absorption and greatly increased bioavailability. Of equally 
great importance is the finding that methylation results in derivatives with increased intrinsic ability to 
inhibit cancer cell proliferation, as shown in cancers of the oral cavity [54] as well as in the intestine 
[62]. The potential therapeutic utility of the methylated flavones has also been advanced by finding 
that methylation reduces the possibility of toxic side-effects and confers increased solubility. Future 
studies should be focused on studies demonstrating their clinical effectiveness. 
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